Who Paid My Doc
Ginny Ryan Buresh
Reproductive Endocrinology Seattle, WA Medical Doctor
NPI 1285624981 CMS profile 1253975
1959 Ne Pacific St, Seattle, WA 98195
General payments
$36
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Ginny Ryan Buresh of Seattle, WA is reported in the CMS Open Payments database as having received $36 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 5th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $17 | 1 | |
| 2021 | General | $18 | 1 |
Beside peers
- Ginny Ryan Buresh
- Reproductive Endocrinology median
- Middle half of Reproductive Endocrinology
- National median
In program year 2025, general payments to Ginny Ryan Buresh were reported at $0. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.
Show as a table
| Year | Ginny Ryan Buresh | Reproductive Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $196 | $77–$425 | $163 |
| 2020 | $0 | $81 | $35–$182 | $114 |
| 2021 | $18 | $102 | $43–$247 | $132 |
| 2022 | $17 | $139 | $62–$303 | $149 |
| 2023 | $0 | $141 | $65–$285 | $160 |
| 2024 | $0 | $144 | $65–$302 | $164 |
| 2025 | $0 | $141 | $66–$285 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
13
Drug cost
$1,381
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Estradiol-Norethindrone Acetat Estradiol/Norethindrone Acet | Brand | 13 | $1,381 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Reproductive Endocrinology in Washington
Lora Shahine
Reproductive Endocrinology · Seattle, WA
Richard Scott
Reproductive Endocrinology · Spokane, WA
Kathleen Lin
Reproductive Endocrinology · Seattle, WA
Jamie Massie
Reproductive Endocrinology · Bellevue, WA
Julie Lamb
Reproductive Endocrinology · Seattle, WA
Michael Opsahl
Reproductive Endocrinology · Kirkland, WA
Related records
Reproductive Endocrinology in Washington
Practitioners in the same specialty and state, ranked by reported value.
All Reproductive Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Washington
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.